Hepatobiliary circulation and dominant urinary excretion of homogentisic acid in a mouse model of alkaptonuria.
hepatobiliary circulation
homogentisic acid
organic acids
tyrosine disorders
tyrosine metabolites
Journal
Journal of inherited metabolic disease
ISSN: 1573-2665
Titre abrégé: J Inherit Metab Dis
Pays: United States
ID NLM: 7910918
Informations de publication
Date de publication:
15 Mar 2024
15 Mar 2024
Historique:
revised:
28
02
2024
received:
18
12
2023
accepted:
29
02
2024
medline:
15
3
2024
pubmed:
15
3
2024
entrez:
15
3
2024
Statut:
aheadofprint
Résumé
Altered activity of specific enzymes in phenylalanine-tyrosine (phe-tyr) metabolism results in incomplete breakdown of various metabolite substrates in this pathway. Increased biofluid concentration and tissue accumulation of the phe-tyr pathway metabolite homogentisic acid (HGA) is central to pathophysiology in the inherited disorder alkaptonuria (AKU). Accumulation of metabolites upstream of HGA, including tyrosine, occurs in patients on nitisinone, a licenced drug for AKU and hereditary tyrosinaemia type 1, which inhibits the enzyme responsible for HGA production. The aim of this study was to investigate the phe-tyr metabolite content of key biofluids and tissues in AKU mice on and off nitisinone to gain new insights into the biodistribution of metabolites in these altered metabolic states. The data show for the first time that HGA is present in bile in AKU (mean [±SD] = 1003[±410] μmol/L; nitisinone-treated AKU mean [±SD] = 45[±23] μmol/L). Biliary tyrosine, 3(4-hydroxyphenyl)pyruvic acid (HPPA) and 3(4-hydroxyphenyl)lactic acid (HPLA) are also increased on nitisinone. Urine was confirmed as the dominant elimination route of HGA in untreated AKU, but with indication of biliary excretion. These data provide new insights into pathways of phe-tyr metabolite biodistribution and metabolism, showing for the first time that hepatobiliary excretion contributes to the total pool of metabolites in this pathway. Our data suggest that biliary elimination of organic acids and other metabolites may play an underappreciated role in disorders of metabolism. We propose that our finding of approximately 3.8 times greater urinary HGA excretion in AKU mice compared with patients is one reason for the lack of extensive tissue ochronosis in the AKU mouse model.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Alkaptonuria Society
ID : 1101052
Informations de copyright
© 2024 The Authors. Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM.
Références
Kretchmer N, Etzwiler DD. Disorders associated with the metabolism of phenylalanine and tyrosine. Pediatrics. 1958;21(3):445-475. doi:10.1542/peds.21.3.445
La Du BN, Zannoni VG, Laster L, Seegmiller JE. The nature of the defect in tyrosine metabolism in alcaptonuria. J Biol Chem. 1958;230(1):251-260.
Ranganath LR, Milan A, Hughes A, et al. Homogentisic acid is not only eliminated by glomerular filtration and tubular secretion but also produced in the kidney in alkaptonuria. J Inherit Metab Dis. 2020;43(4):737-747.
La Du BN, O'Brien WM, Zannoni VG. Studies on ochronosis. I. The distribution of homogentisic acid in Guinea pigs. Arthritis Rheum. 1962;5(1):81-87. doi:10.1002/art.1780050110
Zannoni VG, Malawista SE, La Du BN, Studies on ochronosis. II. Studies on benzoquinoneacetic acid, a probable intermediate in the connective tissue pigmentation of alcaptonuria. Arthritis Rheum Published online. 1962;5:547-556. doi:10.1002/art.1780050603
Phornphutkul C, Introne WJ, Perry MB, et al. Natural history of alkaptonuria. N Engl J Med. 2002;347:2111-2121. doi:10.1056/nejmoa021736
Ranganath LR, Cox TF. Natural history of alkaptonuria revisited: analyses based on scoring systems. J Inherit Metab Dis. 2011;34:1141-1151. doi:10.1007/s10545-011-9374-9
Ranganath LR, Jarvis JC, Gallagher JA. Recent advances in management of alkaptonuria (invited review; best practice article). J Clin Pathol. 2013;66(5):367-373. doi:10.1136/jclinpath-2012-200877
Braconi D, Millucci L, Bernardini G, Santucci A. Oxidative stress and mechanisms of ochronosis in alkaptonuria. Free Radic Biol Med. 2015;88:70-80. doi:10.1016/j.freeradbiomed.2015.02.021
Ranganath LR, Psarelli EE, Arnoux JB, et al. Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2020;8(9):762-772. doi:10.1016/S2213-8587(20)30228-X
Ranganath LR, Khedr M, Milan AM, et al. Nitisinone arrests ochronosis and decreases rate of progression of alkaptonuria: evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre. Mol Genet Metab. 2018;125(1-2):127-134. doi:10.1016/j.ymgme.2018.07.011
Preston AJ, Keenan CM, Sutherland H, et al. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone. Ann Rheum Dis. 2014;73(1):284-289. doi:10.1136/annrheumdis-2012-202878
Keenan CM, Preston AJ, Sutherland H, et al. Nitisinone arrests but does not reverse ochronosis in alkaptonuric mice. JIMD Rep. 2015;24:45-50. doi:10.1007/8904_2015_437
van Ginkel WG, Jahja R, Huijbregts SCJ, et al. Neurocognitive outcome in tyrosinemia type 1 patients compared to healthy controls. Orphanet J Rare Dis. 2016;11(1):87. doi:10.1186/s13023-016-0472-5
McKiernan PJ. Nitisinone for the treatment of hereditary tyrosinemia type I. Expert Opin Orphan Drugs. 2013;1:491-497. doi:10.1517/21678707.2013.800807
White A, Tchan MC. Nitisinone-induced keratopathy in alkaptonuria: a challenging diagnosis despite clinical suspicion. JIMD Rep. 2018;40:7-9. doi:10.1007/8904_2017_56
Stewart RMK, Briggs MC, Jarvis JC, Gallagher JA, Ranganath L. Reversible keratopathy due to hypertyrosinaemia following intermittent low-dose nitisinone in alkaptonuria: a case report. JIMD Rep. 2014;17:1-6. doi:10.1007/8904_2014_307
Ranganath L, Khedr M, Evans LA, Bygott H, Luangrath E, West E. Vitiligo, alkaptonuria, and nitisinone-a report of three families and review of the literature. JIMD Rep. 2021;61(1):25-33. doi:10.1002/jmd2.12225
Khedr M, Judd S, Briggs MC, et al. Asymptomatic corneal keratopathy secondary to hypertyrosinaemia following low dose nitisinone and a literature review of tyrosine keratopathy in alkaptonuria. JIMD Rep. 2018;40:31-37. doi:10.1007/8904_2017_62
Roberts NB, Curtis SA, Milan AM, Ranganath LR. The pigment in alkaptonuria relationship to melanin and other coloured substances: a review of metabolism, composition and chemical analysis. JIMD Rep. 2015;24:51-66. doi:10.1007/8904_2015_453
Chow WY, Norman BP, Roberts NB, et al. Pigmentation chemistry and radical-based collagen degradation in alkaptonuria and osteoarthritic cartilage. Angew Chem Int Ed Engl. 2020;59(29):11937-11942. doi:10.1002/ANIE.202000618
Chow WY, Taylor AM, Reid DG, Gallagher JA, Duer MJ. Collagen atomic scale molecular disorder in ochronotic cartilage from an alkaptonuria patient, observed by solid state NMR. J Inherit Metab Dis. 2011;34(6):1137-1140. doi:10.1007/s10545-011-9373-x
Gallagher JA, Dillon JP, Sireau N, Timmis O, Ranganath LR. Alkaptonuria: an example of a “fundamental disease”-a rare disease with important lessons for more common disorders. Semin Cell Dev Biol. 2016;52:53-57. doi:10.1016/j.semcdb.2016.02.020
Taylor AM, Wlodarski B, Prior IA, et al. Ultrastructural examination of tissue in a patient with alkaptonuric arthropathy reveals a distinct pattern of binding of ochronotic pigment. Rheumatology. 2010;49(7):1412-1414. doi:10.1093/rheumatology/keq027
Ranganath LR, Milan AM, Hughes AT, et al. Suitability of nitisinone in alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid. Ann Rheum Dis. 2016;75(2):362-367. doi:10.1136/annrheumdis-2014-206033
Norman BP, Davison AS, Hickton B, et al. Comprehensive biotransformation analysis of phenylalanine-tyrosine metabolism reveals alternative routes of metabolite clearance in Nitisinone-treated alkaptonuria. Metabolites. 2022;12(10):927. doi:10.3390/metabo12100927
Ranganath LR, Hughes AT, Davison AS, et al. Revisiting quantification of phenylalanine/tyrosine flux in the ochronotic pathway during long-term nitisinone treatment of alkaptonuria. Metabolites. 2022;12(10):920. doi:10.3390/metabo12100920
Milan AM, Hughes AT, Davison AS, et al. Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of alkaptonuria. Sci Rep. 2019;9(1):1-9. doi:10.1038/s41598-019-46033-x
Boyer JL. Bile formation and secretion. Compr Physiol. 2013;3(3):1035-1078. doi:10.1002/cphy.c120027
Hughes JH, Liu K, Plagge A, et al. Conditional targeting in mice reveals that hepatic homogentisate 1,2-dioxygenase activity is essential in reducing circulating homogentisic acid and for effective therapy in the genetic disease alkaptonuria. Hum Mol Genet. 2019;28(23):3928-3939.
Keppler D, König J, Büchler M. The canalicular multidrug resistance protein, cMRP/MRP2, a novel conjugate export pump expressed in the apical membrane of hepatocytes. Adv Enzym Regul. 1997;37:321-333. doi:10.1016/s0065-2571(96)00013-1
König J, Nies AT, Cui Y, Leier I, Keppler D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta. 1999;1461(2):377-394. doi:10.1016/s0005-2736(99)00169-8
Avadhanula S, Introne WJ, Auh S, et al. Assessment of thyroid function in patients with alkaptonuria. JAMA Netw Open. 2020;3(3):e201357. doi:10.1001/jamanetworkopen.2020.1357
Hughes AT, Milan AM, Davison AS, et al. Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry. Ann Clin Biochem. 2015;52(5):597-605. doi:10.1177/0004563215571969
Hughes A, Milan A, Christensen P, et al. Urine homogentisic acid and tyrosine: simultaneous analysis by liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;963:106-112.
Hughes AT, Milan AM, Shweihdi E, Gallagher J, Ranganath L. Method development and validation for analysis of phenylalanine, 4-hydroxyphenyllactic acid and 4-hydroxyphenylpyruvic acid in serum and urine. JIMD Rep. 2022;63(4):341-350. doi:10.1002/jmd2.12287
Segar JL, Balapattabi K, Reho JJ, Grobe CC, Burnett CML, Grobe JL. Quantification of body fluid compartmentalization by combined time-domain nuclear magnetic resonance and bioimpedance spectroscopy. Am J Physiol Regul Integr Comp Physiol. 2021;320(1):R44-R54. doi:10.1152/ajpregu.00227.2020
Stechman MJ, Ahmad BN, Loh NY, et al. Establishing normal plasma and 24-hour urinary biochemistry ranges in C3H, BALB/c and C57BL/6J mice following acclimatization in metabolic cages. Lab Anim. 2010;44(3):218-225. doi:10.1258/la.2010.009128
Debray D, El Mourabit H, Merabtene F, et al. Diet-induced dysbiosis and genetic background synergize with cystic fibrosis transmembrane conductance regulator deficiency to promote cholangiopathy in mice. Hepatol Commun. 2018;2(12):1533-1549. doi:10.1002/hep4.1266
Pedreira F, Tepperman J. Bile flow rate and cholesterol content in mice fed a gallstone-inducing diet. Am J Phys. 1964;206:635-640. doi:10.1152/ajplegacy.1964.206.3.635
Meneton P, Ichikawa I, Inagami T, Schnermann J. Renal physiology of the mouse. Am J Physiol Renal Physiol. 2000;278(3):F339-F351. doi:10.1152/ajprenal.2000.278.3.F339
Yamazaki M, Suzuki H, Sugiyama Y. Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm Res. 1996;13(4):497-513. doi:10.1023/a:1016077517241
Norman BP, Davison AS, Hughes JH, et al. Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism. Genes Dis. 2022;9(4):1129-1142. doi:10.1016/j.gendis.2021.02.007
Bülow C, Rosenberg J. Intrahepatic gallstones in patient with alkaptonuria. Ugeskr Laeger. 2009;171(26):2198-2199.
Chang TM, Bourget L, Lister C. A new theory of enterorecirculation of amino acids and its use for depleting unwanted amino acids using oral enzyme-artificial cells, as in removing phenylalanine in phenylketonuria. Artif Cells Blood Substit Immobil Biotechnol. 1995;23(1):1-21. doi:10.3109/10731199509117665
Bröer A, Klingel K, Kowalczuk S, Rasko JEJ, Cavanaugh J, Bröer S. Molecular cloning of mouse amino acid transport system B0, a neutral amino acid transporter related to Hartnup disorder. J Biol Chem. 2004;279(23):24467-24476. doi:10.1074/jbc.M400904200
Laberge C, Lescault A, Grenier A, et al. Oral loading of homogentisic acid in controls and in obligate heterozygotes for hereditary tyrosinemia type I. Am J Hum Genet. 1990;47(2):329-337.
Russell W, Duthie G. Plant secondary metabolites and gut health: the case for phenolic acids. Proc Nutr Soc. 2011;70(3):389-396. doi:10.1017/S0029665111000152
Montagutelli X, Lalouette A, Coudé M, Kamoun P, Forest M, Guénet JL. aku, a mutation of the mouse homologous to human alkaptonuria, maps to chromosome 16. Genomics. 1994;19(1):9-11. doi:10.1006/geno.1994.1004
Han S, Zhang R, Jain R, et al. Circadian control of bile acid synthesis by a KLF15-Fgf15 axis. Nat Commun. 2015;6:7231. doi:10.1038/ncomms8231
Norman BP, Davison AS, Ross GA, et al. A comprehensive LC-QTOF-MS metabolic phenotyping strategy: application to alkaptonuria. Clin Chem. 2019;65(4):530-539. doi:10.1373/clinchem.2018.295345